KDNY News and Press, Chinook Therapeutics Inc Com From 05/22/23

SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 21, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is inve...

2023-05-19 14:59:05 ET Summary Sparsentan, a key competitor, falters in the Phase 3 DUPLEX study for FSGS, opening potential market opportunities for Chinook's atrasentan. Atrasentan's trial design in ALIGN may increase its chances of success compared to sparsentan. Chinook ha...

2023-05-17 09:28:09 ET Regarding safety, Divan pointed to the safety database from the earlier SONAR trial, as well as indications that atrasentan has better liver safety than Filspari. For further details see: Chinook defended at Guggenheim following short report

SAN FRANCISCO, May 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/KDNY Contact An Attorney Now: KDNY@hbsslaw.com ...

2023-05-16 12:39:57 ET Editor's note: Jonathan Block, the author of this article, has no relation to Muddy Waters founder Carson Block. For further details see: Chinook Therapeutics down 5% following Muddy Waters short report

BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Chinook Therapeutics, Inc. (NASDAQ: KDNY) for potential securities law violations. Investors who have lost money in their Chinook Therapeutics, Inc. investment should contact the firm to learn more about how they mi...

2023-05-16 11:49:50 ET Chinook Therapeutics ( NASDAQ: KDNY ) stock fell ~6% on Tuesday after the company said it is collaborating with Ionis Pharmaceuticals ( NASDAQ: IONS ) to discover, develop and sell an antisense oligonucleotide (ASO) therapy for a rare, severe chr...

SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chron...

2023-05-09 18:05:33 ET Chinook Therapeutics press release ( NASDAQ: KDNY ): Q1 GAAP EPS of -$0.85. Revenue of $1.8M (-33.3% Y/Y). Cash, cash equivalents and marketable securities totaled $357.4 million at March 31, 2023, compared to $385.3 million at December 31, 2022....